homebusiness Newscompanies NewsZydus Lifesciences receives USFDA inspection report with zero observation for its Ahmedabad unit

Zydus Lifesciences receives USFDA inspection report with zero observation for its Ahmedabad unit

In July, the USFDA closed the inspection at Zydus Lifesciences' Pharmez unit in Ahmedabad with a voluntary action indicated (VAI) recommendation in the EIR. The US drug regulator conducted an inspection at the unit between March 20 and March 24, 2023.

Profile image

By CNBCTV18.com Sept 20, 2023 11:54:11 AM IST (Updated)

Listen to the Article(6 Minutes)
2 Min Read
Zydus Lifesciences receives USFDA inspection report with zero observation for its Ahmedabad unit
Zydus Lifesciences Ltd has received an establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA) for its facility at Pharmez in Ahmedabad with nil observations.

Share Market Live

View All

The facility named ‘SEZ 2’ was inspected from July 3-7, the company said in filing to the stock exchanges on Tuesday, September 19. This was a Pre-Approval Inspection (PAI) and had concluded with nil observations, Zydus Lifesciences informed the bourses.
In July, the USFDA closed the inspection at Zydus Lifesciences' Pharmez unit in Ahmedabad with a voluntary action indicated (VAI) recommendation in the EIR. The US drug regulator conducted an inspection at the unit between March 20 and March 24, 2023.
Last week, Zydus Lifesciences received final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, a contraceptive patch comprising a combination of hormone medication.
Last month, the pharmaceutical firm received final approval from the USFDA for Isotretinoin Tablets, which are used in the treatment of severe cystic acne. Also, it obtained final clearance from the USFDA to manufacture and market Indomethacin suppositories, which is used to treat arthritis.
The Ahmedabad headquartered pharma major manufactures and markets a broad range of active pharmaceutical ingredients (API) and formulations.
The Zydus group has research facilities across Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim. It also has manufacturing and research units in the US and Brazil. The company operates outside India with licensing agreements with global multinationals.
Shares of Zydus Lifesciences were trading 0.64 percent lower at Rs 639.35 apiece on BSE at 9:26 AM on Wednesday.

Most Read

Share Market Live

View All
Top GainersTop Losers
CurrencyCommodities
CurrencyPriceChange%Change